Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006).
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 03 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 03 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2009 New trial record